Pomalidomide-C3-NH2 is primarily utilized in the development of targeted cancer therapies, particularly for multiple myeloma. Its structure allows for conjugation with other molecules, enabling the creation of antibody-drug conjugates (ADCs) or small molecule-drug conjugates (SMDCs) that specifically target cancer cells while minimizing damage to healthy tissues. This compound is also explored in proteolysis-targeting chimeras (PROTACs), where it helps degrade disease-causing proteins by recruiting E3 ubiquitin ligases. Additionally, its modified form is studied for improved pharmacokinetics and reduced off-target effects, making it a promising candidate for next-generation cancer treatments.